Table 3.
Network meta-analysis results of the risk ratio of adverse events in patients with the following interventions: ORS=Oral semaglutide, SUS=Subcutaneous semaglutide, GLP = GLP-1 RA comparator, and PLC=Placebo.
| Network comparison, adverse events | |||
|---|---|---|---|
| SUSrowhead | |||
| 0.12 (−0.30, 0.54) | ORS | ||
| 0.20 (−0.13, 0.53) | 0.08 (−0.32, 0.48) | GLP | |
| 0.15 (−0.20, 0.50) | 0.03 (−0.29, 0.36) | −0.05 (−0.42, 0.33) | PLC |